个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Li, Z.-G[a] ; Hu, J.-K[b] ; Li, X.-P[c] ; Yang, Y[a] ; Li, X.-F[d] ; Xu, J.-H[e] ; Zhang, X[f] ; Xu, J[g] ; Bao, C.-D[h] ; He, D.-Y[i] ; Li, Z.-J[j] ; Wang, G.-C[k] ; Zuo, X.-X[l] ; Liu, Y[m] ; Xiao, Z.-Y[n] ; Chen, J.-W[o] ; Xin, X.-F[p] ; Li, J.-Y[q] ; Jiang, L.-D[r] ; Liu, M.-R[s] ; Ji, F[s] ; Li, C.-G[s] ;
机构： [a]Peking University People’s Hospital, Beijing, China [b]Jiangxi Pingxiang People’s Hospital, Pingxiang, China [c]The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China [d]Qilu Hospital of Shandong University, Jinan, China [e]The First Affiliated Hospital of Anhui Medical University, Hefei, China [f]Guangdong General Hospital, Guangzhou, China [g]First Affiliated Hospital of Kunming Medical University, Kunming, China [h]Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China [i]GuangHua Hospital, Shanghai, China [j]First Affiliated Hospital of Bengbu Medical College, Bengbu, China [k]China-Japan Friendship Hospital, Beijing, China [l]Xiangya Hospital of Central South University, Changsha, China [m]West China Hospital of Sichuan University, Chengdu, China [n]First Affiliated Hospital of Shantou University Medical College, Shantou, China [o]The Second Xiangya Hospital of Central South University, Changsha, China [p]Ningbo First Hospital, Ningbo, China [q]Zhuzhou Central Hospital, Zhuzhou, China [r]Zhongshan Hospital, Fudan University, Shanghai, China [s]Eli Lilly and Company, Shanghai, China
出处：
DOI： 10.1007/s12325-020-01572-y
ISSN：

关键词： Baricitinib China Rapid onset Rheumatoid arthritis

摘要：
Introduction: Baricitinib is an oral, selective inhibitor of Janus kinase which demonstrates clinical efficacy in patients with rheumatoid arthritis (RA). This report aims to analyze the onset time of baricitinib in Chinese patients with moderately to severely active RA who had an inadequate response to methotrexate. Methods: This post hoc analysis evaluated clinical improvements of Chinese patients treated with baricitinib 4 mg once daily compared with placebo, based on data from a phase 3 study RA-BALANCE. Efficacy measures including American College of Rheumatology 20% (ACR20) response, ACR core set values, Disease Activity Score modified to include the 28 diarthrodial joint count (DAS28) using high-sensitivity C-reactive protein (hsCRP), DAS28-erythrocyte sedimentation rate, Simplified Disease Activity Index, Clinical Disease Activity Index, DAS28-hsCRP ≤ 3.2 response (low disease activity), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) were evaluated at weeks 1, 2, 4, 8, 12, 14, 16, 20, and 24 (except for FACIT-F evaluated every 4 weeks). A logistic regression model and an analysis of covariance model were used to analyze treatment comparisons of categorical and continuous measures, respectively. Results: Statistically significant (p ≤ 0.05) improvements were observed as early as week 1 or 2 for the baricitinib group compared to placebo in almost all main efficacy measures. For other outcomes including 66 swollen joint count, 68 tender joint count, FACIT-F, and DAS28-hsCRP ≤ 3.2 response rate, differences were evident (p ≤ 0.05) by week 4 in the baricitinib group compared with placebo. Significant improvements in all efficacy measures were sustained through 24 weeks. Conclusions: Baricitinib demonstrated a rapid onset of efficacy on ACR20 response, ACR core set values, disease activity, and patient-reported outcome improvements in Chinese patients from RA-BALANCE. Trial Registration: ClinicalTrials.gov identifier, NCT02265705. © 2020, Springer Healthcare Ltd., part of Springer Nature.

基金：
Sponsorship for this study and Rapid Service Fee were funded by Eli Lilly and Company.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 3 区 医学：研究与实验 3 区 药学
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：研究与实验 3 区 药学
JCR分区：
出版当年[2021]版：
Q2 PHARMACOLOGY & PHARMACY Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [a]Peking University People’s Hospital, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Li Z.-G,Hu J.-K,Li X.-P,et al.Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE[J].ADVANCES IN THERAPY.2021,38(1):772-781.doi:10.1007/s12325-020-01572-y.
APA：
Li, Z.-G,Hu, J.-K,Li, X.-P,Yang, Y,Li, X.-F...&Li, C.-G.(2021).Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.ADVANCES IN THERAPY,38,(1)
MLA：
Li, Z.-G,et al."Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE".ADVANCES IN THERAPY 38..1(2021):772-781

相关文献

[1]Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE. [2]Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study [3]SATISFACTION OF PATIENTS AND PHYSICIANS WITH TREATMENTS FOR RHEUMATOID ARTHRITIS: A NATIONWIDE SURVEY IN CHINA [4]Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study(Open Access) [5]Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients [6]Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China. [7]EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE) [8]Kunxian for the Treatment of Rheumatoid Arthritis [9]An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis (RA-BEYOND) [10]An Interdigitated Aptasensor to Detect Interleukin-6 for Diagnosing Rheumatoid Arthritis in Serum.

资源点击量：52537 今日访问量：0 总访问量：1562 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)